newsfilter
← Latest News
Business Wire·

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Three-year term intended to advance preclinical development of ReSonance Up to $12 million of development costs to be contributed by William Demant Invest Lineage Cell Therapeutics, Inc. (NYSE American and TASE: